Significantly more patients with chronic hepatitis B virus infection achieved functional cure at week 72 after treatment with ...
The sneaky virus poses serious health threats if it goes on to become a chronic disease. Clinical trial results suggest a new drug may cure 1 in 5 of those cases.
Across two large trials, roughly 20% of people treated with bepirovirsen had undetectable levels of the virus after stopping ...
By Bhanvi Satija LONDON, May 28 (Reuters) - GSK said its experimental chronic hepatitis B drug helped nearly one in five ...
Chronic hepatitis B (CHB) is a long-term infection of the liver caused by the hepatitis B virus (HBV). While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the ...
Douglas T. Dieterich, MD, Director, Institute for Liver Medicine and Professor of Medicine at Icahn School of Medicine in New York City, focuses on the emerging use of hepatitis B surface antigen, ...
CARLSBAD, Calif.-- (BUSINESS WIRE)--May 28, 2026-- ...
A major clinical trial found that one in five people with chronic hepatitis B could control the virus without further ...
Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the lower limit of detection (LLOD), is associated with better clinical outcomes of ...
Hepatitis B is sometimes referred to as the "silent killer" because people often lack symptoms – and yet the severe, long-term form of the disease can cause liver failure and death. But new evidence ...
A first-of-its-kind drug for hepatitis B is letting some patients stop treatment without showing signs of the dangerous liver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results